<DOC>
	<DOCNO>NCT00199017</DOCNO>
	<brief_summary>This study evaluate efficacy tolerability treatment T-lymphoblastic lymphoma ( T-LBL ) accord protocol acute lymphoblastic leukemia . Patients receive one year intensive cyclical chemotherapy additional prophylaxis central nervous system ( CNS ) relapse intrathecal therapy cranial irradiation mediastinal irradiation induction chemotherapy .</brief_summary>
	<brief_title>German Multicenter Trial Treatment Newly Diagnosed T-lymphoblastic Lymphoma Adults</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Cladribine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Vindesine</mesh_term>
	<mesh_term>Thioguanine</mesh_term>
	<criteria>Tlymphoblastic lymphoma ( bone marrow [ BM ] involvement &lt; 25 % ) Aged 1565 year ( 5565 year biologically young ) Written informed consent Severe complication due lymphoma secondary disease TLBL second malignancy active second malignancy Cytostatic pretreatment LBL ( exception emergency treatment ) Pregnancy Severe psychiatric illness circumstance may compromise cooperation patient inform consent Participation study interfere study treatment</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>T-LBL</keyword>
	<keyword>Treatment</keyword>
	<keyword>De novo</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Adult</keyword>
	<keyword>Lymphoma , lymphoblastic , T-cell</keyword>
</DOC>